Veracyte

At the Morgan Stanley Healthcare Conference, Veracyte presented a diversification strategy centered on selective acquisitions, expanding the evidence base and new products for prostate, breast, thyroid and bladder cancer. With the acquisition of Convergent Genomics, Veracyte adds the urine‑based bladder cancer biomarker UroAmp to its portfolio; commercialization is planned for late 2028 and is not expected to materially affect the 2026 EBITDA guidance. Decipher and Afirma revenues grew strongly in the second quarter (about 20% and roughly 17–18%, respectively), and management is targeting long‑term adjusted EBITDA margins of about 25%. Veracyte sees potential for a total volume of nearly 1 million tests per year with further guideline support and ongoing product launches. » Plus sur de.investing.com

Veracyte is acquiring Convergent Genomics for $150 million in cash plus up to $30 million in milestone payments tied to reimbursement successes. With the acquisition, Veracyte adds the UroAmp technology for analyzing tumor DNA in urine for non‑muscle‑invasive bladder cancer to its portfolio. A first test is expected to reach the market by the end of 2028 depending on reimbursement timelines; Veracyte also plans to expand UroAmp to additional indications. Ongoing operating costs of Convergent are already included in the adjusted 2026 EBITDA forecast, so that forecast remains unchanged. » Plus sur de.investing.com

Veracyte reported a strong quarter with an earnings beat and raised full-year guidance, driving a notable share advance. Management cited continued double-digit Decipher volume growth and improved Afirma performance after a workflow upgrade that cut no-result rates. Meridian Small Cap Growth Fund highlighted the company's durable testing revenue, expanding menu and upcoming launches (Prosigna and TrueMRD) as evidence of a multi-year growth runway. » Plus sur finance.yahoo.com